A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
NCT01876771
Recruiting
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is... Read More
Gender:
ALL
Ages:
Between 14 years and 90 years
Trial Updated:
08/05/2025
Locations: Cross Cancer Institute, Edmonton, Alberta
Conditions: Carcinoma, Neuroendocrine
Register for Updates
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
NCT07094789
Recruiting
The goal of this clinical trial is to evaluate the safety and initial effectiveness of Magnetic Resonance-guided focused ultrasound neuromodulation using the Next Generation Dome Helmet (NGDH) device in patients with treatment-resistant depression. This is a prospective, single-arm, non-randomized study. Participants will: * Undergo two focused ultrasound treatment sessions targeting nodes of the cortical-striatal-thalamic circuit (CSTC) , spaced four weeks apart. * Return for follow-up visits... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Treatment-Resistant Depression, Treatment-resistant Depression (TRD)
Register for Updates
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830
Recruiting
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: Preferred Research Partners NWA, LLC, Fayetteville, Arkansas +26 locations
Conditions: Treatment Resistant Depression
Register for Updates
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551
Recruiting
The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
08/05/2025
Locations: Childrens Hospital of Alabama, Birmingham, Alabama +45 locations
Conditions: Osteogenesis Imperfecta
Register for Updates
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
NCT04903080
Recruiting
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood. A new gene, called the H... Read More
Gender:
ALL
Ages:
Between 1 year and 22 years
Trial Updated:
08/05/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +12 locations
Conditions: Ependymoma
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Alexander City, Alabama +211 locations
Conditions: Acute Coronary Syndrome
Register for Updates
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377
Recruiting
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Amicis Research Center, Northridge, California +68 locations
Conditions: Primary Membranous Nephropathy
Register for Updates
TIDHI Mental Health in IBD Patients Study
NCT07013578
Recruiting
The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the onl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Toronto Immune and Digestive Health Institute, North York, Ontario
Conditions: Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)
Register for Updates
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT04289142
Recruiting
Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investiga... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/05/2025
Locations: Royal Columbian Hospital, Vancouver, British Columbia +5 locations
Conditions: Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders, Mental Disorders, Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Signs and Symptoms, Dexmedetomidine, Hypnotics and Sedatives, Central Nervous System Depressants, Physiological Effects of Drugs, Analgesics, Non-Narcotic, Analgesics, Molecular Mechanisms of Pharmacological Action
Register for Updates
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
NCT06965998
Recruiting
The goal of this clinical trial, called a pilot study or a feasibility study, is to test the study plan and to find out whether enough participants will join a larger study and accept the study procedures. This type of study includes a small number of participants so it is not expected to prove how safe the treatment is or how well the treatment works. The main question it hopes to answer is: 1.What is the average number of patients that are recruited per month during the 12 month study period... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: The Ottawa Hospital, Ottawa, Ontario +1 locations
Conditions: SVT, Thrombosis, Superficial Vein Thrombosis
Register for Updates
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +212 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
NCT05980767
Recruiting
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/05/2025
Locations: Hamilton General Hospital, Hamilton, Ontario +1 locations
Conditions: Neuropathy;Peripheral
Register for Updates